Abstract:Varicella-zoster virus (VZV) infection causes two distinct clinical conditions. Primary varicella infection results in chickenpox, a contagious rash illness typically seen among children. VZV can reactivate years after the initial infection to cause herpes zoster (HZ) and lead to post-herpetic neuralgia, a common complication resulting in persistent pain that may last for years after the zoster rash resolves. A person's risk of having longer lasting and more severe pain associated with HZ increases with age. Since the introduction of VZV vaccines, the rates of infection, hospitalizations, and mortality have declined. In this review, we discuss in detail current VZV vaccines available for the prevention of VZV and HZ infections. Varilrix (GSK Biologicals, UK), Varivax (Merck, USA) and the combined measles, mumps, rubella, and varicella (MMRV) vaccine contain the live attenuated Oka strain of VZV for routine varicella vaccination. While Zostavax is the only HZ vaccine currently approved for use in the United States and the European Union [EMEA, 2011], a subunit vaccine candidate called HZ/su has recently shown improved efficacy for zoster prevention in two clinical trial phase III studies. VariZIG, a post-exposure prophylactic, uses zoster immune globulin to prevent VZV infection in those who have recently been in contact with VZV but lack evidence of varicella immunity and are contraindicated to receive the varicella vaccine. Further, we discuss the skin tropic and neurotropic factor VZV ORF7 gene and its involvement in varicella infection, reactivation and latency in ganglia. Ultimately, these studies can contribute to the development of a neuroattenuated vaccine candidate against varicella or a vector for delivery of other virus antigens.

Progress in the treatment and prevention of varicella

Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs

Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

Varicella-zoster virus post-exposure management and prophylaxis: A review

Advances and Perspectives in the Management of Varicella-Zoster Virus Infections

Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections

Clinical Features of Varicella-Zoster Virus Infection

Research Progress of Varicella Epidemiological Features and Prevention Strategies

The Investigation and Analysis of Varicella Vaccine Immunization Effect in Yuecheng District

Varicella Pneumonia in Immunocompetent Adults: Symptomatic and Asymptomatic Cases

Efficacy of varicella (VZV) vaccination: an update for the clinician

Varicella Zoster Virus (VZV) Infection: A Comprehensive Review of Chickenpox

Molecular studies of Varicella zoster virus

Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States

Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella.

Clinical and molecular aspects of the live attenuated Oka varicella vaccine

Myths and Misconceptions: Varicella-Zoster Virus Exposure, Infection Risks, Complications, and Treatments

Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review.

Fifteen-minute consultation: Prevention and treatment of chickenpox in newborns

Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus

Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV)